Update cookies preferences

/

•

•

Cipla’s conservative approach is beginning to hurt | The Morning Context

LONGREAD
/
Business

Cipla’s conservative approach is beginning to hurt

The drugmaker’s reluctance to part with cash may have given it one of the strongest balance sheets in Indian pharma, but investors are increasingly rewarding risk takers.

26 July, 2026•10 min

0

26 July, 2026•10 min

0

Getting your Trinity Audio player ready...

Cipla’s conservative approach is beginning to hurt

More in Business

Story image

Akasa, Air India Express or SpiceJet: plenty on offer for Adani’s airline play

Prince M. Thomas

Story image

Akasa, Air India Express or SpiceJet: plenty on offer for Adani’s airline play

A regulatory easing could see the billionaire’s conglomerate move from running airports to owning an airline—an idea he is warming up to, with multiple options open.

Prince M. Thomas

Story image

Suits and countersuits fly between IPO-bound Zetwerk and Ayr Energy

Suits and countersuits fly between IPO-bound Zetwerk and Ayr Energy

Story image

BSE and NSE’s money-with-morals indices struggle to justify their existence

BSE and NSE’s money-with-morals indices struggle to justify their existence

Story image

Ambanis double down but Reliance’s growth engines sputter

The Morning Context team

Ambanis double down but Reliance’s growth engines sputter

The Morning Context team

Story image

Tata Consumer Products struggles with Capital Foods, its most expensive buy

Tata Consumer Products struggles with Capital Foods, its most expensive buy

Story image

Groww just can’t seem to shake off its derivatives dependence

Groww just can’t seem to shake off its derivatives dependence

You may also like

Story image

Dr. Reddy’s wants to be India’s fifth largest drugmaker. What will it take?

The stock market has taken note of the company’s ambitious plans in the domestic market. But the path ahead is far from easy.

Neethi Lisa Rojan

Story image

Indian pharma exporters protesting against new regulations is not a good look

The rules require exporters of certain drugs to get an NOC from importing countries—a small but much-needed step to restoring India’s credibility in the global pharma market.

Story image

Why is Swiggy catching flak for its latest quick-delivery promise?

The food and grocery delivery company’s idea of providing prescription drugs in 10 minutes is facing resistance from traditional pharma players.

Stories Events Thought Leadership On the Record About Us Careers

India Edition

India Edition

India Middle East Startups Longreads Stock Markets Current Affairs Banking & Fintech Renewables CODA Opinion Who reads us

Current Affairs

Banking & Fintech

/

•

•

LONGREAD
/
Business

Cipla’s conservative approach is beginning to hurt

The drugmaker’s reluctance to part with cash may have given it one of the strongest balance sheets in Indian pharma, but investors are increasingly rewarding risk takers.

26 July, 2026•10 min

0

26 July, 2026•10 min

0

Getting your Trinity Audio player ready...

Cipla’s conservative approach is beginning to hurt

More in Business

Story image

Akasa, Air India Express or SpiceJet: plenty on offer for Adani’s airline play

Prince M. Thomas

Story image

Akasa, Air India Express or SpiceJet: plenty on offer for Adani’s airline play

A regulatory easing could see the billionaire’s conglomerate move from running airports to owning an airline—an idea he is warming up to, with multiple options open.

Prince M. Thomas

Story image

Suits and countersuits fly between IPO-bound Zetwerk and Ayr Energy

Suits and countersuits fly between IPO-bound Zetwerk and Ayr Energy

Story image

BSE and NSE’s money-with-morals indices struggle to justify their existence

BSE and NSE’s money-with-morals indices struggle to justify their existence

Story image

Ambanis double down but Reliance’s growth engines sputter

The Morning Context team

Ambanis double down but Reliance’s growth engines sputter

The Morning Context team

Story image

Tata Consumer Products struggles with Capital Foods, its most expensive buy

Tata Consumer Products struggles with Capital Foods, its most expensive buy

Story image

Groww just can’t seem to shake off its derivatives dependence

Groww just can’t seem to shake off its derivatives dependence

You may also like

Story image

Dr. Reddy’s wants to be India’s fifth largest drugmaker. What will it take?

The stock market has taken note of the company’s ambitious plans in the domestic market. But the path ahead is far from easy.

Neethi Lisa Rojan

Story image

Indian pharma exporters protesting against new regulations is not a good look

The rules require exporters of certain drugs to get an NOC from importing countries—a small but much-needed step to restoring India’s credibility in the global pharma market.

Story image

Why is Swiggy catching flak for its latest quick-delivery promise?

The food and grocery delivery company’s idea of providing prescription drugs in 10 minutes is facing resistance from traditional pharma players.

Context is everything.

Detailed stories on technology startups, business and economic current affairs.

Reads

Home Page
India
Middle East
The Gulf Review
Startups
State of the Unicorns
Stock Markets
Current Affairs
Opinion

Technology Startups

Artificial Intelligence
Quick Commerce
E-commerce
Deep tech
Consumer brands
Electric vehicles
Agri-tech
Ed-tech
Fin-tech
Software-as-a-Service
Food delivery

Business

Aviation
Conglomerates
Banking & Finance
Energy
Stock Markets
SEBI
RBI
Mutual Funds
Retail
Media
Telecom

Opinion

Today’s Opinion
CODA
Strategy, defence, diplomacy
Economy
World Affairs
Love & Family
Technology
Agriculture

The Company

About Us
Who Reads Us
On The Record
Thought Leadership
Events
Careers
Editorial Code

Individual Subscription
Corporate Subscription
University & College Subscription
Student Subscription
Lifetime Patron Membership
Gift Subscription
Free Subscription

© 2026 Slowform Holdings Ltd.Terms of Service Privacy Policy Grievance Redressal Help